# US 2016/0354332 A1 · Therapeutic strategies for treating mitochondrial disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354332 A1
- Document ID: US20160354332A1
- Status: Published application
- Kind: A1
- Application number: 15/177,243
- Filed: 2016-06-08
- Published: 2016-12-08
- Earliest claimed: 2015-06-08
- Assignees: Whitehead Institute for Biomedical Research; Massachusetts Institute of Technology; Howard Hughes Medical Institute
- Applicants: Whitehead Institute for Biomedical Research; Massachusetts Institute of Technology
- Inventors: David M. Sabatini; Kivanc Birsoy; Matthew George Vander Heiden; Lucas Bryan Sullivan; Dan Yi Gui
- Web page: https://patentgrep.com/patent/US20160354332A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/52: Purines, e.g. adenine
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are methods, compositions, and systems for treating mitochondrial disorders (e.g., MERRF, MELAS, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia, diabetes mellitus and deafness, lactic acidosis, Leber's hereditary optic neuropathy, Wolff-Parkinson-White syndrome, Leigh syndrome, NARP, myoneurogenic gastrointestinal encephalopathy, mitochondrial DNA depletion syndrome) or neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease) by administering aspartate, or an analog or prodrug thereof, or an agent that increases intracellular levels of aspartate. Pharmaceutical compositions and kits for use in treating mitochondrial disorders and neurodegenerative diseases are also described herein. Also provided are methods for treating disease by modulating the redox state of a cell, and methods of treating a proliferative disease by administering a cytosolic aspartate aminotransferase (GOT1) inhibitor.

## Claims

### Claim 1

A method of treating a mitochondrial disorder comprising administering to a subject in need thereof, a therapeutically effective amount of aspartate, or an analog thereof; an agent that increases intracellular aspartate levels; or an agent that increases intracellular levels of an electron acceptor capable of oxidizing NADH.

### Claim 2

A method of treating a neurodegenerative disease comprising administering to a subject in need thereof, a therapeutically effective amount of aspartate, or an analog thereof; an agent that increases intracellular aspartate levels; or an agent that increases intracellular levels of an electron acceptor capable of oxidizing NADH.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the agent is aspartate, a prodrug of aspartate, or an analog thereof.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the agent is asparagine, oxaloacetate, a purine, or pyrimidine, or an analog thereof.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the agent is a protein or peptide comprising aspartate.

### Claim 10 (depends on 1)

The method of claim 1, wherein the agent is pyruvate, or an analog thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein the agent is α-ketobutyrate, or an analog thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the agent inhibits the catabolism of aspartate or pyruvate, or analogs thereof, or inhibits uptake of pyruvate by the liver.

### Claim 13 (depends on 1)

The method of claim 1, wherein the agent is an activator of aspartate aminotransferase GOT1.

### Claim 14 (depends on 1)

The method of claim 1, wherein the agent increases uptake of aspartate, or analogs thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the agent is an activator of SLC1A3 or increases expression of SLC1A3.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein the agent is a modulator, inverse activator, inhibitor of asparagine synthetase, or down-regulates expression of asparagine synthetase.

### Claim at position 17

18-19. (canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the mitochondrial disorder is associated with a mitochondrial respiration defect.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein the mitochondrial disorder is myoclonic epilepsy with red ragged fibers (MERRF); mitochondrial encephalomyopathy, lactic acidosis, and stroke like symptoms (MELAS); Kearns-Sayre syndrome (KSS); chronic progressive external ophthalmoplegia (CPEO); diabetes mellitus and deafness (DAD); lactic acidosis; Leber's hereditary optic neuropathy (LHON); Wolff-Parkinson-White syndrome; Leigh syndrome; neuropathy, ataxia, retinitis pigmentosa, and ptosis (NARP); myoneurogenic gastrointestinal encephalopathy (MNGIE); or mitochondrial DNA depletion syndrome (MDS).

### Claim at position 21

23-30. (canceled)

### Claim 31

A method of treating a proliferative disease comprising administering to a subject in need thereof an inhibitor of aspartate aminotransferase GOT1.

### Claim at position 23

32-34. (canceled)

### Claim 35

A pharmaceutical compositions comprising a therapeutically effective amount aspartate, or an analog thereof, or an agent that increases intracellular levels of aspartate, or an analog thereof, for use in treating a mitochondrial disorder.

### Claim 36

(canceled)

### Claim 37

A method of treating a disease by administering to a subject in need thereof a substrate, or a pharmaceutically acceptable salt stereoisomer, tautomer, polymorph, or prodrug thereof, of an enzyme which converts the substrate to a first product, wherein a concentration of a second product of the enzyme is increased.

### Claim at position 27

38-52. (canceled)

### Claim 53 (depends on 31)

A method of claim 31, wherein the proliferative disease is a cancer associated with a defect in oxidative phosphorylation.

### Claim 54 (depends on 53)

The method of claim 53, wherein the defect in oxidative phosphorylation comprises a mutation in mitochondrial DNA.

### Claim 55 (depends on 53)

The method of claim 53, wherein the defect in oxidative phosphorylation comprises a mutation in a gene encoding succinate dehydrogenase, fumarate hydratase, or isocitrate dehydrogenase.

### Claim at position 31

56-60. (canceled)
